Studying multiple sclerosis with digital health tools
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study observes people with multiple sclerosis (MS) to collect health data and samples over time. It aims to use digital tools and artificial intelligence to better understand the disease and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with multiple sclerosis (MS) by a doctor using standard criteria.
- You must be willing to take part in study visits, questionnaires, and provide samples.
- Your diagnosis should be recent (less than 3 years), or you are currently having a flare (relapse), or your MS is changing to a more progressive form.
- You must be able to speak and understand French, English, or German.
- You cannot be pregnant at the start of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how multiple sclerosis (MS) affects your thinking, sleep, and tiredness. It compares people with MS who have at least mild fatigue to people without MS who also have sleep problems, to understand these issues better.
This study follows people with multiple sclerosis over time using a smartphone app and clinic visits. It aims to better understand the disease and improve care.
This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.
This study uses MRI scans to measure how the brain changes over time in people with multiple sclerosis (MS). It may help researchers understand why some people with MS experience more disability, which could lead to better treatments.
This study looks at different immune cells in blood and, sometimes, spinal fluid (CSF) to understand what’s driving multiple sclerosis (MS) or early MS-like symptoms. Your participation may help researchers better explain the disease and potentially improve how it’s diagnosed or treated.
This study tests different ways of monitoring people with relapsing-remitting MS who are reducing or stopping their medication. It aims to find the safest follow-up approach and may help guide future treatment decisions for those with stable disease.
Hear when a new Multiple Sclerosis, Relapsing-Remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.